A team of researchers from MIT, Brigham and Women’s Hospital, and Harvard Medical School has made a significant breakthrough in the development of a new treatment for alopecia areata, an autoimmune skin disorder characterized by hair loss. This condition, which affects individuals of all ages, including children, has limited treatment options for most patients.
The researchers have engineered a microneedle patch that can be painlessly applied to the scalp. This patch releases therapeutic drugs that help rebalance the immune response at the site of application, effectively halting the autoimmune attack that causes hair loss.
In a groundbreaking study on mice, the researchers observed that this treatment led to hair regrowth and a substantial reduction in inflammation at the treatment site. Crucially, it avoided systemic immune effects elsewhere in the body. This strategy could potentially be extended to treat other autoimmune skin diseases such as vitiligo, atopic dermatitis, and psoriasis, the researchers suggest.
Natalie Artzi, a principal research scientist at MIT’s Institute for Medical Engineering and Science, an associate professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, and an associate faculty member at the Wyss Institute of Harvard University, explains, “Instead of suppressing the immune system, we’re now focusing on regulating it precisely at the site of antigen encounter to generate immune tolerance.”
Artzi and Jamil R. Azzi, an associate professor of medicine at Harvard Medical School and Brigham and Women’s Hospital, served as the senior authors of the study, which was published in the journal Advanced Materials. Nour Younis, a Brigham and Women’s postdoc, and Nuria Puigmal, a Brigham and Women’s postdoc and former MIT research affiliate, were the lead authors of the paper.